|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
DE19756212A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19756235A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
WO2000009132A1
(en)
*
|
1998-08-12 |
2000-02-24 |
Smithkline Beecham Corporation |
Calcilytic compounds
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
MXPA03001245A
(es)
*
|
2000-08-11 |
2003-05-27 |
Wyeth Corp |
Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
|
|
IL155093A0
(en)
|
2000-09-29 |
2003-10-31 |
Glaxo Group Ltd |
Morpholin-acetamide derivatives for the treatment on inflammatory diseases
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
KR100927915B1
(ko)
*
|
2005-03-17 |
2009-11-19 |
화이자 인코포레이티드 |
통증 치료에 유용한 ｎ-(ｎ-설폰일아미노메틸)사이클로프로판카복사마이드 유도체
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
WO2007053498A1
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
AU2009264273B2
(en)
|
2008-06-24 |
2015-01-22 |
Onxeo Dk, Branch Of Onxeo S.A., France |
Squaric acid derivatives as inhibitors of the nicotinamide
|
|
EP2342181A1
(en)
|
2008-08-29 |
2011-07-13 |
Topo Target A/S |
Novel urea and thiourea derivatives
|
|
CA2768338A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
NZ607638A
(en)
|
2010-09-03 |
2015-04-24 |
Genentech Inc |
Novel compounds and compositions for the inhibition of nampt
|
|
CA2809391A1
(en)
|
2010-09-03 |
2012-03-08 |
Genentech, Inc. |
4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
|
|
BR112013005108A2
(pt)
|
2010-09-03 |
2016-05-10 |
Forma Tm Llc |
compostos e composições de guanidina para a inibição de nampt
|
|
EP2621903B1
(en)
*
|
2010-09-29 |
2017-03-01 |
Intervet International B.V. |
N-heteroaryl compounds
|
|
KR20140009251A
(ko)
|
2010-11-15 |
2014-01-22 |
애브비 인코포레이티드 |
Ｎａｍｐｔ 및 ｒｏｃｋ 억제제
|
|
MX2013005479A
(es)
|
2010-11-15 |
2013-06-12 |
Abbvie Inc |
Inhibidores de nampt.
|
|
CA2834746A1
(en)
|
2011-05-04 |
2012-11-08 |
Forma Tm, Llc |
Novel compounds and compositions for the inhibition of nampt
|
|
WO2012154194A1
(en)
|
2011-05-09 |
2012-11-15 |
Forma Tm, Llc |
Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
|
|
CN104583194A
(zh)
|
2012-05-11 |
2015-04-29 |
艾伯维公司 |
作为nampt抑制剂的哒嗪和吡啶衍生物
|
|
WO2013170118A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Thiazolecarboxamide derivatives for use as nampt inhibitors
|
|
EP2852585A1
(en)
|
2012-05-11 |
2015-04-01 |
AbbVie Inc. |
Nampt inhibitors
|
|
US9187472B2
(en)
|
2012-05-11 |
2015-11-17 |
Abbvie Inc. |
NAMPT inhibitors
|
|
HK1215579A1
(zh)
|
2012-11-29 |
2016-09-02 |
Karyopharm Therapeutics, Inc. |
被取代的2，3-二氫苯並呋喃基化合物和其用途
|
|
CN105492437B
(zh)
|
2013-07-03 |
2018-05-11 |
卡尔约药物治疗公司 |
取代的苯并呋喃基和苯并噁唑基化合物及其用途
|
|
US9994558B2
(en)
|
2013-09-20 |
2018-06-12 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
MA42655A
(fr)
|
2015-08-18 |
2021-04-07 |
Karyopharm Therapeutics Inc |
Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
KR20230144096A
(ko)
|
2016-10-18 |
2023-10-13 |
씨젠 인크. |
니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
US11931414B2
(en)
|
2017-04-27 |
2024-03-19 |
Seagen Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
EP3746079A1
(en)
|
2018-01-31 |
2020-12-09 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
JP7643874B2
(ja)
|
2018-05-04 |
2025-03-11 |
リメディー プラン，インコーポレーテッド |
がん幹細胞を標的化するがん治療
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
KR20220110744A
(ko)
|
2019-11-06 |
2022-08-09 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
WO2022241257A1
(en)
|
2021-05-13 |
2022-11-17 |
Remedy Plan, Inc. |
Nampt inhbitors and uses thereof
|